改良Mayo内镜评分(MMES)评估节段性愈合可补充预测溃疡性结肠炎患者的长期临床结局
这项前瞻性观察研究纳入150例中重度溃疡性结肠炎起始生物制剂治疗的患者,中位随访61个月,按内镜活动度分为内镜改善、仅节段性内镜应答和无内镜应答三组,发现仅节段性内镜应答组的长期临床结局介于另两组之间,MMES有助于预测长期结局,但内镜改善仍是最强预测因素。
要点
- MMES可评估节段性内镜改善,补充预测溃疡性结肠炎长期结局。
- 仅节段性内镜应答组长期结局介于内镜改善组与无应答组之间。
- 内镜改善(MES≤1)仍是长期结局的最强预测因素。
核心结论
- MMES在预测溃疡性结肠炎长期结局方面显示出益处,但内镜改善仍是最强预测因素。
研究设计与样本
- 前瞻性观察研究,纳入2014年1月至2017年9月连续起始生物制剂治疗的中重度溃疡性结肠炎患者,共150例(女性48%,中位年龄42岁,中位病程7年),中位随访61个月。
- 基线及第8/14周进行临床与内镜评估,采用改良Mayo评分评估临床活动度,MES和MMES评估内镜活动度。
- 按内镜活动度变化分为三组:内镜改善(MES≤1)、仅节段性内镜应答(MES>1但MMES下降≥30%)和无内镜应答(其余所有患者)。
主要发现
- 共69例患者达到内镜改善,27例为仅节段性内镜应答,54例无内镜应答。
- 仅节段性内镜应答组的长期临床结局介于内镜改善组与无内镜应答组之间(临床复发无生存率log rank p=0.003,停药无生存率和结肠切除无生存率均p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Current endoscopic scoring systems for ulcerative colitis (UC) do not consider the extent of mucosal inflammation. The modified Mayo endoscopic score (MMES) was developed to detect segmental endoscopic improvement. We evaluated the ability of the MMES to predict long-term clinical outcomes and compared it to the widely used Mayo endoscopic subscore (MES). METHODS: Consecutive patients with moderate to severe UC starting biological therapy were enrolled between January 2014 and September 2017 in this prospective observational study. A clinical and endoscopic evaluation was performed at baseline and at week 8/14. A modified Mayo score was used to grade clinical activity, MES and MMES were used to evaluate endoscopic activity. Patients were divided into 3 groups according to the evolution of endoscopic activity, namely endoscopic improvement (MES ≤ 1), segmental endoscopic response only (MES > 1, but decrease in MMES ≥ 30%) or no endoscopic response (all others). Over the follow-up period clinical relapse-, discontinuation- and colectomy-free survival were assessed. RESULTS: A total of 150 patients were included (48% female, median age 42 years, median disease duration 7 years) with a median follow-up of 61 months. We identified 69 patients with endoscopic improvement, 27 with segmental endoscopic response and 54 without endoscopic response. Patients with segmental endoscopic response showed intermediate long-term clinical outcomes as compared to the other two groups (log rank p = 0.003 for clinical relapse-, and p < 0.001 for both discontinuation- and colectomy-free survival). CONCLUSIONS: The MMES exhibited a benefit in predicting long-term outcome in UC even though endoscopic improvement remains the strongest predictor.
引用
- Lenfant M, Verstockt B, Sabino J, et al. The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023. PMID: 37843544. doi:10.1111/apt.17753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。